Clinical Review

Focus on menopause

Author and Disclosure Information

 

References

Estrogen options. I ask my patients about their preferences, but I typically recommend transdermal or non-oral estradiol formulations for my menopausal patients. The most commonly prescribed non-oral menopausal estrogen is the patch—as they are convenient, come in a wide range of doses, and are generic and generally affordable. There are also US Food and Drug Administration (FDA)–approved transdermal gels and creams, and a vaginal ring that provides systemic estrogen, but these options are typically more expensive than the patch. All non-oral estrogen formulations are composed of estradiol, which is especially nice for a patient preferring “bioidentical HT.”

Many of our patients like the idea that they are using “natural” HT. I inform them that bioidentical is a marketing term rather than a medical term, but if their goal is to take the same hormones that their ovaries made when they were younger, they should use FDA-approved formulations of estradiol and progesterone for their menopausal HT symptoms. I do not recommend compounded bioidentical HT due to concerns regarding product quality and safety. The combination of FDA-approved estradiol patches and oral micronized progesterone provides a high quality, carefully regulated bioidentical HT regimen. For women greatly preferring an oral estrogen, oral estradiol with micronized progesterone is an option.

In addition to patient preference for natural HT, the reasons that I encourage women to consider the estradiol transdermal patch for their menopausal HT include:

  1. no increased risk of venous thromboembolic events when physiologically dosed menopausal estradiol therapy is provided by a skin patch (observational data).1 With oral estrogens, even when dosed for menopause, VTE risk increases, as coagulation factors increase due to the first-pass hepatic effect. This does not occur with non-oral menopausal estrogens.
  2. no increased risk of gallbladder disease, which occurs with oral estrogen therapy (observational data)2
  3. possibly lower risk of stroke when low-dose menopausal HT is provided via skin patch (observational data)3
  4. convenience—the patches are changed once or twice weekly
  5. wide range of doses available, which optimizes identifying the lowest effective dose and decreasing the dose over time.

Progestogen options. Progestogens may be given daily or cyclically. Use of daily progestogen typically results in amenorrhea, which is preferred by most women. Cyclic use of a progestogen for 12-14 days each month results in a monthly withdrawal bleed, which is a good option for a woman experiencing bothersome breakthrough bleeding with daily progestogen. Use of a progestogen-releasing IUD is an off-label alternative for endometrial protection with menopausal HT. As discussed earlier, as many women prefer bioidentical HT, one of our preferred regimens is to provide transdermal estradiol with FDA-approved oral micronized progesterone. There are several patches that combine estradiol with a progestogen, but there is not a lot of dosing flexibility and product choice. There also is an approved product available that combines oral estradiol and micronized progesterone in one tablet.

Scheduling follow-up

OBG Management: Now that you have started the opening case patient on HT, how often are you going to monitor her for treatment?

Dr. Shifren: Women will not experience maximum efficacy for hot flash relief from their estrogen therapy for 3 months, so I typically see a patient back at 3 to 4 months to assess side effects and symptom control. I encourage women to reach out sooner if they are having a bothersome side effect. Once she is doing well on an HT regimen, we assess risks and benefits of ongoing treatment annually. The goal is to be certain she is on the lowest dose of estrogen that treats her symptoms, and we slowly decrease the estrogen dose over time.

Breast cancer risk

OBG Management: In your presentation, you mentioned that the risk of breast cancer does not increase appreciably with short-term use of HT. Is it possible to define short term?

Dr. Shifren: In the Women’s Health Initiative (WHI), a large double-blind, randomized, placebo-controlled trial of menopausal HT, there was a slight increase in breast cancer risk after approximately 4 to 5 years of use in women using estrogen with progestogen.4 I share with patients that this increased risk is about the same as that of obesity or drinking more than 1 alcoholic beverage daily. As an increased risk of breast cancer does not occur for several years, a woman may be able to take hormones for bothersome symptoms, feel well, and slowly come off without incurring significant breast cancer risk. In the WHI, there was no increase in breast cancer risk in women without a uterus randomized to estrogen alone.

Regarding cardiovascular risk, in the WHI, an increased risk of cardiovascular events generally was not seen in healthy women younger than age 60 and within 10 years of the onset of menopause.5 Benefits of HT may not outweigh risks for women with significant underlying cardiovascular risk factors, even if they are younger and close to menopause onset.

Continue to: The importance of shared decision making...

Pages

Recommended Reading

Menopause symptoms negatively affect women’s work
MDedge ObGyn
Nonhormonal drug fezolinetant found safe for hot flashes in yearlong study
MDedge ObGyn
Early estrogen loss increases cardiovascular risk in women
MDedge ObGyn
Plant-based diet cut hot flashes 78%: WAVS study
MDedge ObGyn
Menopause an independent risk factor for schizophrenia relapse
MDedge ObGyn
Nicotine blocks estrogen production in women’s brains
MDedge ObGyn
Multiple menopause symptoms linked to increased cardiovascular risk
MDedge ObGyn
Hormone therapy–depression link may depend on mode of administration
MDedge ObGyn
USPSTF holds firm on postmenopausal hormone recommendations
MDedge ObGyn
Does subclinical hyperthyroidism raise fracture risk?
MDedge ObGyn